Impact of
iGlarLixi
on Glycaemic Control Depth and Variability in Asian Pacific People With Type 2 Diabetes: A Post Hoc Analysis of
LixiLan
‐O‐
Jiaying Ni, Jingyi Lu, Fei Gao, Min Li, Minlu Zhang, Qin Du, Lei Kang, Danfeng Peng, Jian Zhou ABSTRACT
Aims
To evaluate the impact of iGlarLixi on the depth of glycaemic control, glycaemic variability (GV) and postprandial glucose (PPG) control versus insulin glargine 100 U/mL (iGlar) or lixisenatide (Lixi) in Asian Pacific individuals with type 2 diabetes (T2D).
Materials and Methods
A post hoc analysis was conducted of two phase 3 trials in individuals with suboptimally controlled T2D on oral antidiabetic drugs (LixiLan‐O‐AP) or basal insulin (LixiLan‐L‐CN). Outcomes were evaluated from baseline to end‐of‐treatment (EOT; Week 24 or 30, respectively). Using self‐monitoring of blood glucose (SMBG) profiles, glycaemic control depth was assessed via derived time in tight range (dTITR; 3.9–7.8 mmol/L). GV was evaluated using standard deviation (SD) of SMBG, high blood glucose index (HBGI), mean absolute glucose (MAG), and mean amplitude of glycaemic excursions (MAGE). PPG at 0.5, 1, and 2 h was measured via standardised meal tests.
Results
From baseline to EOT, iGlarLixi provided greater increases in dTITR versus iGlar (least squares mean difference 15.03%) or Lixi (29.14%) in LixiLan‐O‐AP, and versus iGlar (15.93%) in LixiLan‐L‐CN. At EOT, > 50% dTITR rate was 67.2%, 41.1% and 26.5% with iGlarLixi, iGlar and Lixi in LixiLan‐O‐AP, respectively, and 53.6% and 26.4% with iGlarLixi and iGlar in LixiLan‐L‐CN. iGlarLixi provided generally greater reductions in SD of SMBG, HBGI, MAG, MAGE and 0.5‐, 1‐ and 2‐h PPG versus iGlar or Lixi and greater 2‐h PPG < 10.0 mmol/L achievement rates at EOT.
Conclusion
iGlarLixi improves dTITR, GV, and PPG control versus iGlar or Lixi in Asian Pacific individuals with T2D.